I'm thrilled to sit down with Ivan Kairatov, a biopharma expert with extensive experience in research and development, as well as a deep understanding of technology and innovation in the industry. Today, we’ll dive into the critical intersection of cancer research, advocacy, and policy, exploring
Today, we’re thrilled to sit down with Ivan Kairatov, a renowned biopharma expert with extensive experience in research and development, particularly in the realm of oncology and innovative technologies. With a deep understanding of the industry’s evolving landscape, Ivan offers unique insights
In an era where the pharmaceutical industry grapples with soaring costs and lengthy timelines for bringing new drugs to market, a staggering statistic emerges: it often takes over a decade and billions of dollars to develop a single successful medication, highlighting the urgent need for
In a world where the race to develop life-changing therapies is accelerating at an unprecedented pace, biotech innovators are turning to artificial intelligence to redefine the boundaries of drug discovery, and Absci Corporation, a Seattle-based company listed on NASDAQ under the ticker ABSI,
In a world still grappling with the aftermath of a global health crisis that recorded over 700 million cases and 7 million deaths, the role of COVID-19 vaccines stands as a testament to human ingenuity and scientific progress. These vaccines, developed at an unprecedented pace through years of
Imagine a world where treatments for complex diseases are tailored to an individual’s unique genetic makeup, offering hope to patients who have long been out of options, and Alnylam Pharmaceuticals, a pioneer in RNA interference (RNAi) therapeutics, is turning this vision into reality by joining
